Dissemination Materials Sample Clauses

Dissemination Materials. In this section, we describe the dissemination materials that were produced and/or harnessed in the first half of the project. The strategy shows a wide-reaching approach to peer reviewed publications that target Academia, Industry, and the Clinic, while popularised publications target the General Public in addition to those same groups. Our video content has gained attention, with a fast building YouTube following keen on our content such as recorded talks/webinars, as well as our continuing dissemination campaign surrounding the Virtual Humans film produced in CompBioMed1. Meanwhile, our newsletters, posters, and other materials have kept a steady flow of dissemination into the world throughout the first 25 months of the project.
Sample 1Sample 2
AutoNDA by SimpleDocs
Dissemination Materials. Development of materials for use in national follow-up presentations of project progress and results. Deliverables Deliverable D1: Project internal Internet home page Date due: Month 3 Deliverable D3: Brochure presenting the project Date due: Month 6 Work package Title: ‘Dissemination and Exploitation’ WP No. 16 Starting date: Month No. 1 Duration: 36 months Total Effort: 18 Partners involved R&D Task / Activity of partner Effort: Deliverable D32: Executive summary report of the project Date due: Month 36 Deliverable D33: Follow-up materials to support project progress and results Date due: Month 36 Milestones and criteria Milestone M17: Mid-term follow-up. Date due: Month 19 Consistency demonstrated with work programme and objectives. Milestone M19: Final symposium. Date due: Month 33 Preparations for the final symposium completed. Interrelation with other work packages WP 16 will work towards dissemination, implementation and exploitation of the outputs of WP 2, WP 3, WP 4,WP 5, WP 12, WP 13, WP 14 and WP 15. It will also integrate the technical outputs of these WPs into the Executive summary report.
Sample 1
Dissemination Materials. In addition to the two (2) sets of leaflets and posters committed in the DoW, additional printing materials may be designed on demand at any time, tailored to the event and target audience where they will be used. A new brochure is also expected to be released when milestone MS2.3 is reached (Successful availability of the infrastructure of the FIBRE-BR facilities). This material will be aimed at attracting outside researchers and students to use the facilities to run their experiments. To ensure continuous coverage of project activities, press releases will be produced before and after any FIBRE event. Their respective files will also be available in electronic format on the project web site1. Depending on the targeted audience and the venue where the project will be disseminated, some materials might be produced in Portuguese only. 7 Participation in external events This dissemination plan also expects FIBRE members to attend major related events in the next years, preferably presenting FIBRE outcomes in talks, posters and/or technological demonstrations. The series of events most likely to FIBRE members to attend are:  Brazilian Symposium on Computer Networks and Distributed Systems (SBRC)  Brazilian Symposium on Telecommunications (SBrT 2012)  European Workshop on Software Defined Networks (EWSDN)  Future Internet Assembly  GENI Engineering Conference (GEC)  Open Network Summit  RNP Workshop (WRNP)  XXXXXX Networking Conference (TNC)  TridentCom At the time of writing this deliverable, not all events, dates and locations were defined for 2013 and 2014.
Sample 1
Dissemination Materials. In this section, we describe the dissemination materials that were produced and/or harnessed in the second half of the project. The strategy shows a wide-reaching approach to peer reviewed publications that targets Academia, Industry and the Clinic, while popularised publications target the general public in addition to those same groups. Our video content gains attention thanks to a high number of recorded talks, as well as our major dissemination campaign surrounding the Virtual Humans film. Meanwhile, our newsletters, posters, and other materials have kept a steady flow of dissemination into the world throughout the second half of the project.
Sample 1
Dissemination Materials. Figure 18 Documents library Dissemination materials The ‘Dissemination materials’ directory stores partner contributions relevant to the project‘s dissemination activities e.g. papers, articles, press releases, and posters undertaken during the project duration.
Sample 1
Dissemination Materials. In terms of printed materials for dissemination and networking, the following documents and print templates were identified, and some of them already designed during the first months of the project:
Sample 1
Dissemination Materials 
Sample 1
AutoNDA by SimpleDocs

Related to Dissemination Materials

  • Customer Materials 12.1 The Supplier including any of its employees, agents, consultants, contractors and any third party shall:

  • RELEASE OF BID EVALUATION MATERIALS Requests concerning the evaluation of Bids may be submitted under the Freedom of Information Law. Information, other than statistical or factual tabulations or data such as the Bid Tabulation, shall only be released as required by law after Contract award. Bid Tabulations are not maintained for all procurements. Names of Bidders may be disclosed after Bid opening upon request. Written requests should be directed to the Commissioner.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

  • User Information Any user or usage data or information collected via Station’s digital properties or related to Station’s digital properties, or any information collected from websites operated by Station’s affiliates under this Agreement, shall be the property of Station and/or such affiliates. Advertiser shall have no rights in such information by virtue of this Agreement.

  • Patient Information Each Party agrees to abide by all laws, rules, regulations, and orders of all applicable supranational, national, federal, state, provincial, and local governmental entities concerning the confidentiality or protection of patient identifiable information and/or patients’ protected health information, as defined by any other applicable legislation in the course of their performance under this Agreement.

  • Company Information Subscriber understands that the Company is subject to all the risks that apply to early-stage companies, whether or not those risks are explicitly set out in the Offering Circular. Subscriber has had such opportunity as it deems necessary (which opportunity may have presented through online chat or commentary functions) to discuss the Company’s business, management and financial affairs with managers, officers and management of the Company and has had the opportunity to review the Company’s operations and facilities. Subscriber has also had the opportunity to ask questions of and receive answers from the Company and its management regarding the terms and conditions of this investment. Subscriber acknowledges that except as set forth herein, no representations or warranties have been made to Subscriber, or to Subscriber’s advisors or representative, by the Company or others with respect to the business or prospects of the Company or its financial condition.

  • Client Information (2) Protected Health Information in any form including without limitation, Electronic Protected Health Information or Unsecured Protected Health Information (herein “PHI”);

  • Program Information The Heritage Greece Program is generally described in the literature provided to the Student and available online at: xxxx://xxx.xxx.xxx. It is understood and agreed that the information contained therein is descriptive only and may be changed in the discretion of ACG which reserves the right to make Program changes at any time and for any reason, with or without notice. ACG and/or the Sponsor shall not be liable to the Student because of any such change. ACG reserves all rights, in its sole discre tion, to cancel the Program or any aspect thereof prior to or after departure, and in the case of cancellation after departure, to require the Student to return to the United States, if ACG determines or believes it is in the best interests of the Student.

  • Third Party Materials The Application may display, include, or make available third-party content (including data, information, applications, and other products, services, and/or materials) or provide links to third-party websites or services, including through third- party advertising ("Third-Party Materials"). You acknowledge and agree that Company is not responsible for Third-Party Materials, including their accuracy, completeness, timeliness, validity, copyright compliance, legality, decency, quality, or any other aspect thereof. Company does not assume and will not have any liability or responsibility to you or any other person or entity for any Third-Party Materials. Third-Party Materials and links thereto are provided solely as a convenience to you, and you access and use them entirely at your own risk and subject to such third parties' terms and conditions.

  • PRIVACY INFORMATION Through Your Use of the Website and Services, You may provide Us with certain information. By using the Website or the Services, You authorize the Company to use Your information in the United States and any other country where We may operate.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!